Ace Therapeutics is committed to helping our clients discover, design and develop innovative peptides to accelerate the process of antidiabetic drug development. Our team of experts, with extensive experience in diabetes research and peptide drug discovery, is dedicated to developing antidiabetic peptides with enhanced bioactivity, prolonged duration of action, and improved stability.

Introduction of Antidiabetic Peptide Drugs

Antidiabetic peptide drugs such as insulin and glucagon-like peptide-1 (GLP-1) analogues are emerging as promising agents for the treatment of diabetes, showing significant advantages. They mimic or enhance the action of insulin in the body. Compared with traditional small molecule antidiabetic drugs, active peptide drugs have the unique advantages of low molecular weight, simple structure, clear mechanism of action, and low side effects. Compared to proteins or antibodies, peptide drugs have similar advantages but are much smaller in size and easier to synthesize.

Fig. 1 Advantages, absorption barriers, and delivery strategies of oral antidiabetic peptides. (Ding, B.; et al., 2024)

Our Antidiabetic Peptide Drug Development Services

Ace Therapeutics is committed to providing our clients with one-stop solutions from early discovery of antidiabetic peptide drugs to preclinical efficacy research to accelerate the development of new drugs.

Antidiabetic Peptide Drug Discovery Services

We provide target-based peptide antidiabetic drug discovery services designed to help our clients identify and screen promising therapeutic molecules to help them succeed in subsequent drug development. We are committed to providing customized drug discovery solutions to accelerate our clients' peptide drug discovery process.

• Target identification and validation: We help clients screen and validate potential druggable targets based on diabetes mechanism studies.
• High-throughput synthesis and screening: Rapid screening of potential candidate antidiabetic peptides from synthesized peptide libraries with advanced high-throughput synthesis and screening technologies.
• Lead peptide optimization: We provide our clients with optimized peptide candidates for subsequent drug development through peptide sequence optimization, simulation and bioactivity assessment.

Preclinical Development Services for Antidiabetic Peptide Drugs

We offer a range of specialized tests and services to help clients assess the safety and efficacy of peptide drugs, including but not limited to:

• Evaluation of activity and efficacy of antidiabetic peptides: Select suitable in vitro cellular models and in vivo animal models to evaluate the glucose regulation function and mechanism of action of potential antidiabetic peptides to predict their efficacy.
• ADME & DMPK studies of antidiabetic peptides: Comprehensive ADME and pharmacokinetic profiling to ensure efficacy and stability of peptide drug candidates.
• Safety assessment of antidiabetic peptides: A comprehensive assessment of the toxicological, safety pharmacological, histopathological and safety pharmacological properties of potential antidiabetic peptides.

Our Technology Platform for Antidiabetic Drug Development

• Diabetes mechanism research: Study the genes and biochemical pathways related to diabetes at the molecular and cellular levels, and conduct integration and systematic analysis to provide potential targets and biomarkers for developing of antidiabetic peptide drugs.
• In vivo and in vitro diabetes models: A comprehensive portfolio of diabetes cell, animal models and custom modeling services enables us to help our clients research, discover and develop innovative peptide-based diabetes model.

At Ace Therapeutics, our target-based preclinical peptide antidiabetic drug development services are designed to help clients around the world accelerate their diabetes drug discovery and explore safer, more effective and transformative therapeutic options. Please contact us for more details. Our experienced experts will collaborate with you in developing and advancing new frontiers in diabetes treatment.

Reference

1. Ding, B.; et al. Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives. Acta Pharmaceutica Sinica B. (2024).

• Small Molecule Antidiabetic Drug Development Services
• Protein-Based Antidiabetic Drug Development Services
• Antibody-Based Antidiabetic Drug Development Services
• Glycan-Based Antidiabetic Drug Development Services
• Nucleic Acid-Based Antidiabetic Drug Development Services
• Vaccine Development Services for Diabetes

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators